CN105232627A - Solidago extract and preparation method and medical application thereof - Google Patents
Solidago extract and preparation method and medical application thereof Download PDFInfo
- Publication number
- CN105232627A CN105232627A CN201510770953.0A CN201510770953A CN105232627A CN 105232627 A CN105232627 A CN 105232627A CN 201510770953 A CN201510770953 A CN 201510770953A CN 105232627 A CN105232627 A CN 105232627A
- Authority
- CN
- China
- Prior art keywords
- extract
- herba
- parts
- preparation
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses solidago extract and a preparation method and medical application thereof. The method includes the steps that a, measured by weight, every 100 parts of medical materials are prepared from 80-90 parts of dry solidagos and 10-20 parts of dry mint, mixed, smashed and subjected to heat reflux extraction through a 75% ethanol solution, extracting solutions are combined and concentrated till no alcohol smell exists, and an ethanol extraction concentrated solution is obtained; b, the ethanol extraction concentrated solution obtained in the step a is diluted and is extracted through petroleum ether, ethyl acetate and water-saturated n-butanol, decompression concentration is conducted, and petroleum ether extract, ethyl acetate extract and n-butanol extract are independently obtained; c, the n-butanol extract is dissolved through water and filtered, active ingredients are enriched through macroporous resin, eight column volumes are flushed through 10% ethyl alcohol to remove large-polarity components, 12 column volumes are flushed through 70% ethyl alcohol, 70% eluant is collected, and decompression concentration is conducted to obtain the solidago extract. The solidago extract can be applied to gouty arthritis, and can be developed into medicine for treating gouty arthritis.
Description
Technical field
The present invention relates to Chinese medicine extract field, be specifically related to a kind of Herba Solidaginis extract, the preparation method of this extract and medical usage, this extract can be applied to the medicine of preparation treatment gouty arthritis.
Background technology
Herba Solidaginis is herb or the whole herb with root of feverfew Herba Solidaginis.Gather between summer, autumn.Another name FLOS CHRYSANTHEMI INDICI (" Nanning City's medicine will "), half, limit, mountain perfume (or spice), spill JINHUA (" Jiangxi traditional herbal medicine "), Hemerocallis citrina Baroni Herba Asari, Hemerocallis citrina Baroni Herba Veronicae (" Guangxi Chinese medicinal herbal "), thousand Huang (" the south of Fujian Province traditional herbal medicine "), soil Herba Lycopi, Radix Stemonae, ferrum gold turns " Quanzhou book on Chinese herbal medicine "), Xian grass, little Radix Alangii, Hemerocallis citrina Baroni Herba Kalimeridis, relieve internal heat greatly, RADIX BUPLEURI SCORZONERIFOLII (" Hunan medicine end "), Folium seu radix sidae mysorensis, the bitter Lay of red glue (" east, Fujian book on Chinese herbal medicine "), Herba Veronicae, great Ye Herba Moslae Cavaleriei (" Guangdong Chinese medicine "), snakehead king (" Chinese herbal medicine is commonly used in Shanghai "), JINSUOSHI, Huang all over the mountain, Hemerocallis citrina Baroni (" Zhejiang conventional medical herbs among the people "), yellow Radix Bupleuri (Sichuan).
Former plant Herba Solidaginis perennial herb is high 15 ~ 80 centimetres.Stem is upright, and bottom Glabrous, top is micro-fine hair.Leaf alternate; Avette circular to square, long 1 ~ 5 centimetre, wealthy 0.2 ~ 2.5 centimetre, inferior leads tool handle, have minimum sawtooth, upper leaf is less and narrow, is bordering on full edge, above bottle green, below celadon, the nearly Glabrous in two sides.Panicle, the raceme of being given birth to by axil reassociates and forms; Head inflorescence is little, diameter 5 ~ 8 millimeters, and single life or 2 ~ 4 consor are on the short common peduncle that axil is raw; Phyllary is narrow and sharp, tool dry film matter edge, long 2 ~ 5 millimeters, differs in size, and ordered series of numbers is imbricate arrangement; Holder is bald naked; Peripheral ligulate flower is yellow, female, about 8 pieces; Central cylindrical flower, both sexes, corolla 5 splits, and flower pesticide is polymerized, and base portion is blunt.Achene is closely cylindrical, bald clean or have pubescence. October at florescence.Really November phase.Be born in hill, border.Whole nation most area has distribution.
Summary of the invention
The object of the present invention is to provide a kind of Herba Solidaginis extract, its preparation method and liquid phase analysis method, the pharmaceutical preparation containing this extract and utilize this extract to prepare the purposes of medicine for the treatment of gouty arthritis.
Above-mentioned purpose of the present invention is achieved by technical scheme below:
A kind of Herba Solidaginis extract, this extract is prepared by following methods:
A () by weight, every 100 parts of medical materials comprise dry Herba Solidaginis 80 ~ 90 parts and dry Herba Menthae 10 ~ 20 parts, co-grinding, and with 75% alcoholic solution circumfluence distillation, merge extractive liquid, is concentrated into and obtains ethanol extraction concentrated solution without alcohol taste; B (), by step (a) gained ethanol extraction concentrated solution dilute with water, is used petroleum ether, ethyl acetate and water saturated n-butanol extraction successively, concentrating under reduced pressure, is obtained petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract respectively; C () n-butyl alcohol extract water dissolution, filters, uses macroporous resin enrichment active component, first remove large polar component with 10% alcohol flushing, 8 column volumes, then use 70% ethanol elution, 12 column volumes, collect 70% eluent, concentrating under reduced pressure and get final product.
In order to be controlled the differences between batches of extract prepared by different batches by the method setting up HPLC finger printing, the liquid phase analysis method of described extract is:
Chromatographic column: AgilentZorbaxExtent-C18 post (4.6mm × 250mm, 5 μm);
Mobile phase: A is acetonitrile, and B is 0.5% phosphoric acid solution;
Gradient elution program: 0 ~ 5min, A10% → 15%; 5 ~ 10min, A15% → 48%; 10 ~ 25min, A48% → 78%; 25 ~ 30min, A78% → 10%;
Flow rate of mobile phase: 1.0mLmin
-1; Determined wavelength: 240nm;
Column temperature: 35 DEG C; Sample size: 10 μ L.
Pharmaceutical preparation, the described extract containing treatment effective dose and pharmaceutically acceptable carrier.
The application of described extract in the medicine of preparation treatment gouty arthritis.
The application of described pharmaceutical preparation in the medicine of preparation treatment gouty arthritis.
When extract of the present invention is used as medicine, directly can uses, or use in the form of a pharmaceutical preparation.
Described pharmaceutical preparation contains the Herba Solidaginis extract of the present invention for the treatment of effective dose, and all the other are acceptable on materia medica, nontoxic to humans and animals and pharmaceutically suitable carrier of inertia and/or excipient.
Described pharmaceutically suitable carrier or excipient are that one or more are selected from solid, semisolid and liquid diluent, filler and pharmaceutical preparation adjuvant.Pharmaceutical preparation of the present invention is used with the form of per weight dose.Extract of the present invention is applied to by form that is oral or injection the patient needing treatment.For time oral, tablet, slow releasing tablet, controlled release tablet, capsule, drop pill, micropill, suspensoid, Emulsion, powder or granule, oral liquid etc. can be made into; During for injecting, can be made into aqueous or oily solution, aseptic powder injection, liposome or the Emulsion etc. of sterilizing.
Advantage of the present invention: the present invention by the Herba Solidaginis of drying and Herba Menthae is extracted, remove impurity, enrichment process, the extract with treatment gouty arthritis can be obtained; Liquid phase analysis method provided by the invention may be used for the finger printing setting up this extract, for controlling the differences between batches of extract prepared by different batches.
Accompanying drawing explanation
Fig. 1 is Herba Solidaginis extract HPLC chromatograms.
Detailed description of the invention
Further illustrate essentiality content of the present invention below in conjunction with embodiment, but do not limit scope with this.Although be explained in detail the present invention with reference to preferred embodiment, those of ordinary skill in the art should be appreciated that and can modify to technical scheme of the present invention or equivalent replacement, and does not depart from essence and the scope of technical solution of the present invention.
Embodiment 1: 1. Herba Solidaginis extract is prepared (85 parts of Herba Solidaginiss, 15 portions of Herba Menthaes)
Crude drug source: Herba Solidaginis and Herba Menthae are purchased from Hui nationality's Chinese Medicinal Materials Markets.
Main agents: food-grade ethanol is purchased from Shanghai Ling Feng chemical reagent company limited; Pharmaceutical grade AB-8 macroporous resin is purchased from sky tunami letter resin company limited; Acetonitrile is HPLC level, is purchased from TEDIA; 85% phosphoric acid is HPLC level, is purchased from TEDIA; Chromatographic grade pure water is heartily pure water.
Preparation method: by dry for 8.5kg Herba Solidaginis rhizome and the dry Herba Menthae co-grinding of 1.5kg, with 75% alcoholic solution circumfluence distillation (25L × 3 time), merge extractive liquid, is concentrated into and obtains ethanol extraction concentrated solution (2L) without alcohol taste; Gained ethanol extraction concentrated solution is diluted with water to 3L, petroleum ether (3L × 3 time), ethyl acetate (3L × 3 time) and water saturated n-butyl alcohol (3L × 3 time) is used to extract successively, concentrating under reduced pressure, obtains petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract 232g respectively; (c) n-butyl alcohol extract 1.5L water dissolution, medical absorbent cotton filters, with AB-8 macroporous resin (2kg, column volume 1.5L) deposition activity composition, first use 10% alcohol flushing, 8 column volumes (12L) to remove large polar component, then use 70% ethanol elution, 12 column volumes (18L), collect 70% eluent, concentrating under reduced pressure, obtains Herba Solidaginis extract and is about 150g.
Embodiment 2: 2. Herba Solidaginis extract is prepared (80 parts of Herba Solidaginiss, 20 portions of Herba Menthaes)
Preparation method: by dry for 8.0kg Herba Solidaginis rhizome and the dry Herba Menthae co-grinding of 2.0kg, with 75% alcoholic solution circumfluence distillation (25L × 3 time), merge extractive liquid, is concentrated into and obtains ethanol extraction concentrated solution (2L) without alcohol taste; Gained ethanol extraction concentrated solution is diluted with water to 3L, petroleum ether (3L × 3 time), ethyl acetate (3L × 3 time) and water saturated n-butyl alcohol (3L × 3 time) is used to extract successively, concentrating under reduced pressure, obtains petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract 232g respectively; (c) n-butyl alcohol extract 1.5L water dissolution, medical absorbent cotton filters, with AB-8 macroporous resin (2kg, column volume 1.5L) deposition activity composition, first use 10% alcohol flushing, 8 column volumes (12L) to remove large polar component, then use 70% ethanol elution, 12 column volumes (18L), collect 70% eluent, concentrating under reduced pressure, obtains Herba Solidaginis extract and is about 150g.
Embodiment 3: 3. Herba Solidaginis extract is prepared (90 parts of Herba Solidaginiss, 10 portions of Herba Menthaes)
Preparation method: by dry for 9.0kg Herba Solidaginis rhizome and the dry Herba Menthae co-grinding of 1.0kg, with 75% alcoholic solution circumfluence distillation (25L × 3 time), merge extractive liquid, is concentrated into and obtains ethanol extraction concentrated solution (2L) without alcohol taste; Gained ethanol extraction concentrated solution is diluted with water to 3L, petroleum ether (3L × 3 time), ethyl acetate (3L × 3 time) and water saturated n-butyl alcohol (3L × 3 time) is used to extract successively, concentrating under reduced pressure, obtains petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract 232g respectively; (c) n-butyl alcohol extract 1.5L water dissolution, medical absorbent cotton filters, with AB-8 macroporous resin (2kg, column volume 1.5L) deposition activity composition, first use 10% alcohol flushing, 8 column volumes (12L) to remove large polar component, then use 70% ethanol elution, 12 column volumes (18L), collect 70% eluent, concentrating under reduced pressure, obtains Herba Solidaginis extract and is about 150g.
Embodiment 4: 4. Herba Solidaginis extract is prepared (75 parts of Herba Solidaginiss, 25 portions of Herba Menthaes)
Preparation method: by dry for 7.5kg Herba Solidaginis rhizome and the dry Herba Menthae co-grinding of 2.5kg, with 75% alcoholic solution circumfluence distillation (25L × 3 time), merge extractive liquid, is concentrated into and obtains ethanol extraction concentrated solution (2L) without alcohol taste; Gained ethanol extraction concentrated solution is diluted with water to 3L, petroleum ether (3L × 3 time), ethyl acetate (3L × 3 time) and water saturated n-butyl alcohol (3L × 3 time) is used to extract successively, concentrating under reduced pressure, obtains petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract 232g respectively; (c) n-butyl alcohol extract 1.5L water dissolution, medical absorbent cotton filters, with AB-8 macroporous resin (2kg, column volume 1.5L) deposition activity composition, first use 10% alcohol flushing, 8 column volumes (12L) to remove large polar component, then use 70% ethanol elution, 12 column volumes (18L), collect 70% eluent, concentrating under reduced pressure, obtains Herba Solidaginis extract and is about 150g.
Embodiment 5: 5. Herba Solidaginis extract is prepared (95 parts of Herba Solidaginiss, 5 portions of Herba Menthaes)
Preparation method: by dry for 9.5kg Herba Solidaginis rhizome and the dry Herba Menthae co-grinding of 0.5kg, with 75% alcoholic solution circumfluence distillation (25L × 3 time), merge extractive liquid, is concentrated into and obtains ethanol extraction concentrated solution (2L) without alcohol taste; Gained ethanol extraction concentrated solution is diluted with water to 3L, petroleum ether (3L × 3 time), ethyl acetate (3L × 3 time) and water saturated n-butyl alcohol (3L × 3 time) is used to extract successively, concentrating under reduced pressure, obtains petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract 232g respectively; (c) n-butyl alcohol extract 1.5L water dissolution, medical absorbent cotton filters, with AB-8 macroporous resin (2kg, column volume 1.5L) deposition activity composition, first use 10% alcohol flushing, 8 column volumes (12L) to remove large polar component, then use 70% ethanol elution, 12 column volumes (18L), collect 70% eluent, concentrating under reduced pressure, obtains Herba Solidaginis extract and is about 150g.
Embodiment 6: liquid-phase chromatographic analysis
Need testing solution is prepared: in the brown volumetric flask of extract 5mg to 50mL that Example 1 method is obtained, add 30mL10% acetonitrile solution ultrasonic dissolution, after being cooled to room temperature, continue to add 10% acetonitrile solution standardize solution.Analytical method is as follows:
High performance liquid chromatograph: Agilent1260, binary pump;
Chromatographic column: AgilentZorbaxExtent-C18 post (4.6mm × 250mm, 5 μm);
Mobile phase: A is acetonitrile, and B is 0.5% phosphoric acid solution;
Gradient elution program: 0 ~ 5min, A10% → 15%; 5 ~ 10min, A15% → 48%; 10 ~ 25min, A48% → 78%; 25 ~ 30min, A78% → 10%;
Flow rate of mobile phase: 1.0mLmin
-1; Determined wavelength: 240nm; Column temperature: 35 DEG C; Sample size: 10 μ L.
Analyze with the Herba Solidaginis extract of 10 batches of preparation, carry out chromatographic peak coupling, 1 ~ No. 10 peak all occurs in 10 batch sample chromatograms as a result.Therefore demarcate 10 peaks for total chromatographic peak, set up the HPLC quality control collection of illustrative plates of this extract accordingly, the results are shown in Figure 1.This Herba Solidaginis extract pharmacologically active of 10 batches is similar.
Embodiment 7: extract pharmacological testing
One, materials and methods
1.1 medicines: Herba Solidaginis extract 1. ~ 5. obtain according to embodiment 1 ~ 5 respectively.Colchicines tablets, lot number 100206, specification 0.5mg/s, Banna Pharmacy Industry Co., Ltd., Xishuangbanna; Get 6 colchicine, grinding, adding distil water is to 200mL, and it is 0.15mg/mL colchicine solution that mixing is mixed with concentration.Crystallite Monosodium urate (MSU), with reference to Coderre method, 194mL distilled water adds 6mL1mol/LNaOH, boil, add 1g uric acid, adjust pH to 7.2 with 1mL1mol/LHCl, stir cooling, 4 DEG C of Refrigerator store 24h, remove supernatant, with filter paper, precipitate moisture is blotted, put into 70 DEG C of drying baker and dry 2h, take out, scrape powder, put into mortar pulverization, sieve with the metallic screen in 250 μm, aperture, make MSU powder for subsequent use.
1.2 reagent: uric acid (UA) test kit, lot number: P100121, Shanghai Foxing Changzheng medical science Co., Ltd; Nitric oxide (NO) test kit, lot number: 20110119, Bioengineering Research Institute is built up in Nanjing; Total protein (TP biuret method) test kit, lot number: 110601, thing development in science and technology company limited of Beijing Rui Ji Hang Seng.
1.3 animals: cleaning grade SD rat, male, body weight 200 ~ 220g, is provided by Zhejiang Academy of Medical Sciences, the quality certification number: SCXK (Zhejiang) 20080033.
1.4 instruments: LP123 electronic balance, weighing apparatus factory of Changshu City, made in CCCP 00000153; YLS-7A rat toes capacity measurer, Shandong Academy of Medical Sciences's equipment station; HEMAVET950 animal blood analyser, ADrewScientificGroupCo; Prestige figure SELECTRA-E full automatic biochemical apparatus, Dutch Rittal GmbH.
1.5 experimental techniques and Testing index
1.5.1 animal grouping and administration: rat is divided into 18 groups at random: Normal group, model control group, positive controls (colchicine 0.0015gkg
-1), Herba Solidaginis extract 1. ~ 5. respectively establish 3 dosage group (100mgkg
-1, 200mgkg
-1, 300mgkg
-1), often organize 10.Administration 5d before modeling, 1 time/d, continues administration after modeling.By reagent group respectively gavage give the Herba Solidaginis extract of various dose, Normal group gavage gives the water of respective volume, and positive control drug gavage gives the colchicine medicinal liquid of corresponding dosage.
1.5.2 modeling: get 1000mgMSU and add 9mL normal saline, then add lmL tween 80, heated and stirred, (concentration is 100mgmL to be mixed with 10mLMSU suspension
-1), ankle joint flexing after Rat Right after administration 30min, touch with hands and can lay one's hand on and two apophysis portions, after 75% medical alcohol partly sterilised, insert tibialis inboard leg with No. 6 entry needles ankle joint dorsal part on rear side of left and right from 45 ° of directions, 0.1mLMSU suspension is injected into ankle joint chamber, prepares acute gouty arthritis model, stretch song, rotary motion 2min, rats in normal control group physiological saline solution replaces MSU suspension.
1.5.3 Articular swelling: mark with a circle around ankle joint marking pen in outside, Rat Right metapedes ankle joint trident place before modeling, measures Rat Right foot to mark Volume of Displacement twice, averages as arthritic volume before administration; After modeling, 1h, 4h, 6h, 24h measure Rat Right foot to mark Volume of Displacement, by formulae discovery swelling.
Ankle joint Volume of Displacement (mL) before ankle joint Volume of Displacement (mL) after swelling (mL)=cause is scorching-cause is scorching.
1.5.4 hemanalysis: modeling 24h, after last administration 30min, after having surveyed the Volume of Displacement of appointed part, from the blood sampling of rat retroorbital venous clump 5mL, wherein natural blood coagulation 2h, 3500rmin under 4mL room temperature
-1centrifugal 10min, draw serum, reference reagent box description measures serum UA, NO content in accordance with the law; Another 1mL adds 10 μ LEDTA anticoagulants, uses animal blood analyser to measure leukocyte, neutrophilic granulocyte, lymphocyte quantity in accordance with the law.
1.5.5 biochemical and histological indices: on cellophane with sharp keen blade from Rat Right ankle joint dorsal part fast shut-off fascia, cut whole soft tissue and cartilage that ankle joint trident place removes bone, to weigh and the ice normal saline adding 9 times amount makes 10% tissue homogenate, 3500rmin
-1centrifugal 10min, draw supernatant, reference reagent box description measures total protein, NO content in accordance with the law; Spleen, kidney are got in execution, weigh, and calculate spleen system number and kidney system number.
1.6 statistical analysiss: measurement data data result represents with x ± s, compare between group and adopt t inspection.
Two, result
2.1 Herba Solidaginis extract is on the impact of gouty arthritis rat articular swelling
Compared with Normal group, model control group ankle swelling in rat degree all significantly raises (P<0.01) in 1 ~ 6h after modeling; 1h after modeling, compared with model control group, colchicine group, Herba Solidaginis extract 1. ~ 3. each dosage group ankle swelling in rat degree all significantly decline (P<0.01); 4h after modeling, compared with model control group, colchicine group, Herba Solidaginis extract 1. ~ 3. each dosage group ankle swelling in rat degree all significantly decline (P<0.01); 6h after modeling, compared with model control group, colchicine group, Herba Solidaginis extract 1. ~ 3. high dose group ankle swelling in rat degree all significantly decline (P<0.05); Herba Solidaginis extract 1. ~ 3. in, low dose group ankle swelling in rat degree also has the trend of reduction; Herba Solidaginis extract 4. ~ 5. each dosage group in modeling 24h compared with model group all without significant difference.The results are shown in Table 1 (note: compare with model group, * P<0.05, * * P<0.01).
Table 1 Herba Solidaginis extract in modeling 24h on the impact (x ± s, n=10) of gouty arthritis ankle swelling in rat degree
2.2 impacts on gouty arthritis rat spleen body index, kidney body index
Compared with Normal group, model group kidney body index obviously reduces, and spleen body index obviously raises (P<0.05,0.01); Compared with model control group, colchicine group kidney of rats body index significantly raises, and spleen body index significantly reduces (P<0.05); Herba Solidaginis extract 1. ~ 3. high dose group kidney body index obviously rise (P<0.01), Herba Solidaginis extract 1. ~ 3. each dosage group spleen body index all have decline (P<0.05,0.01) in various degree; Herba Solidaginis extract 4. ~ 5. each dosage group on the impact of rat spleen body index, kidney body index and model group without marked difference.In table 2 (note: compare with model control group, * P<0.05, * * P<0.01).
Table 2 Herba Solidaginis extract is on the impact (x ± s, n=10) of gouty arthritis rat spleen index, renal index
2.3 impacts on leukocyte, neutrophilic granulocyte and lymphocyte level in gouty arthritis rat whole blood
Compared with Normal group, the leukocyte of model control group, neutrophilic granulocyte and lymphocyte quantity have the trend of rising; Compared with model group colchicine and Herba Solidaginis extract 1. ~ 3. the leukocyte of high dose group rat, neutrophilic granulocyte close lymphocyte quantity and obviously reduce (P<0.05,0.01), Herba Solidaginis extract 1. ~ 3. all the other each dosage groups all have reduction trend; Herba Solidaginis extract 4. ~ 5. each dosage group and model control group be than without significant difference.In table 3 (note: compare with model control group, * P<0.05, * * P<0.01).
Table 3 Herba Solidaginis extract is on gouty arthritis rat leukocyte, neutrophilic granulocyte and lymphocyte impact (x ± s, n=10)
2.4 impacts on gouty arthritis rat blood serum UA level
Each group of rat serum uric acid level result result display, compared with Normal group, model group Level of Serum Uric Acid obviously raises (P<0.05); Compared with model group, Herba Solidaginis extract 1. ~ 3. in high dose group rat serum uric acid obviously decline (P<0.05); Herba Solidaginis extract 4. ~ 5. each dosage group and model group be than there are no significant difference.In table 4 (note: compare with model control group, * P<0.05, * * P<0.01).
Table 4 Herba Solidaginis extract is on the impact (x ± s, n=10) of gouty arthritis rat blood serum UA
| Group | Dosage/(mg/kg) | UA/μmol·L -1 |
| Normal group | - | 74.79±19.57* |
| Model control group | - | 92.78±17.96 |
| Colchicine group | 0.0015 | 82.42±21.99 |
| Extract is low dose group 1. | 100 | 79.17±14.48 |
| Extract is middle dosage group 1. | 200 | 72.09±15.66* |
| Extract is high dose group 1. | 300 | 71.70±20.58* |
| Extract is low dose group 2. | 100 | 79.32±14.54 |
| Extract is middle dosage group 2. | 200 | 72.64±15.42* |
| Extract is high dose group 2. | 300 | 71.85±20.49* |
| Extract is low dose group 3. | 100 | 79.21±14.32 |
| Extract is middle dosage group 3. | 200 | 72.38±15.74* |
| Extract is high dose group 3. | 300 | 71.73±20.61* |
| Extract is low dose group 4. | 100 | 92.18±14.21 |
| Extract is middle dosage group 4. | 200 | 91.03±15.51 |
| Extract is high dose group 4. | 300 | 90.31±20.17 |
| Extract is low dose group 5. | 100 | 92.00±14.19 |
| Extract is middle dosage group 5. | 200 | 90.87±15.69 |
| Extract is high dose group 5. | 300 | 90.11±20.05 |
Above-mentioned result of the test shows, Herba Solidaginis extract has therapeutical effect to rat gouty arthritis.In Herba Solidaginis extract, the content of Herba Menthae is most important to its performance therapeutical effect.
Embodiment 8: the preparation of tablet
Obtain extract by embodiment 1 method, add excipient, pelletizing press sheet in itself and excipient weight than the ratio for 1:10.
Embodiment 9: the preparation of oral liquid
By embodiment 1 method first obtained extract, oral liquid method for making makes oral liquid routinely.
Embodiment 10: the preparation of capsule or granule
By embodiment 1 method first obtained extract, add excipient in itself and excipient weight than the ratio for 1:9, make capsule or granule.
Embodiment 11: the preparation of injection
Obtain extract by embodiment 1 method, inject with water, fine straining, injection is made in embedding sterilizing.
Embodiment 12: the preparation of aseptic powder injection
By embodiment 1 method first obtained extract, be dissolved in sterile water for injection, stirring makes molten, filters with aseptic suction funnel, more aseptic fine straining, and be sub-packed in ampoule, after frozen drying, aseptic sealing by fusing obtains injectable powder.
The effect of above-described embodiment is essentiality content of the present invention is described, but does not limit protection scope of the present invention with this.Those of ordinary skill in the art should be appreciated that and can modify to technical scheme of the present invention or equivalent replacement, and does not depart from essence and the protection domain of technical solution of the present invention.
Claims (6)
1. a Herba Solidaginis extract, it is characterized in that described extract is prepared by following methods: (a) by weight, every 100 parts of medical materials comprise dry Herba Solidaginis 80 ~ 90 parts and dry Herba Menthae 10 ~ 20 parts, co-grinding, with 75% alcoholic solution circumfluence distillation, merge extractive liquid, is concentrated into and obtains ethanol extraction concentrated solution without alcohol taste; B (), by step (a) gained ethanol extraction concentrated solution dilute with water, is used petroleum ether, ethyl acetate and water saturated n-butanol extraction successively, concentrating under reduced pressure, is obtained petroleum ether extract, acetic acid ethyl ester extract and n-butyl alcohol extract respectively; C () n-butyl alcohol extract water dissolution, filters, uses macroporous resin enrichment active component, first remove large polar component with 10% alcohol flushing, 8 column volumes, then use 70% ethanol elution, 12 column volumes, collect 70% eluent, concentrating under reduced pressure and get final product.
2. extract according to claim 1, is characterized in that: macroporous resin described in step (c) is AB-8 type macroporous resin.
3. extract according to claim 1, is characterized in that: the liquid phase analysis method of described extract is:
Chromatographic column: AgilentZorbaxExtent-C18 post (4.6mm × 250mm, 5 μm);
Mobile phase: A is acetonitrile, and B is 0.5% phosphoric acid solution;
Gradient elution program: 0 ~ 5min, A10% → 15%; 5 ~ 10min, A15% → 48%; 10 ~ 25min, A48% → 78%; 25 ~ 30min, A78% → 10%;
Flow rate of mobile phase: 1.0mLmin
-1;
Determined wavelength: 240nm;
Column temperature: 35 DEG C;
Sample size: 10 μ L.
4. a pharmaceutical preparation, is characterized in that: the extract according to claim 1 containing treatment effective dose and pharmaceutically acceptable carrier.
5. the application of extract according to claim 1 in the medicine of preparation treatment gouty arthritis.
6. the application of pharmaceutical preparation according to claim 4 in the medicine of preparation treatment gouty arthritis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510770953.0A CN105232627A (en) | 2015-11-12 | 2015-11-12 | Solidago extract and preparation method and medical application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510770953.0A CN105232627A (en) | 2015-11-12 | 2015-11-12 | Solidago extract and preparation method and medical application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105232627A true CN105232627A (en) | 2016-01-13 |
Family
ID=55030626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510770953.0A Withdrawn CN105232627A (en) | 2015-11-12 | 2015-11-12 | Solidago extract and preparation method and medical application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105232627A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105815783A (en) * | 2016-03-22 | 2016-08-03 | 张利文 | Snow lotus herb extract-containing food additive with sleep improving effect |
| CN107343893A (en) * | 2017-07-31 | 2017-11-14 | 海南医学院 | Application of Hainan Stephania epigaea extract on treatment urarthritis preparation is prepared |
-
2015
- 2015-11-12 CN CN201510770953.0A patent/CN105232627A/en not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105815783A (en) * | 2016-03-22 | 2016-08-03 | 张利文 | Snow lotus herb extract-containing food additive with sleep improving effect |
| CN107343893A (en) * | 2017-07-31 | 2017-11-14 | 海南医学院 | Application of Hainan Stephania epigaea extract on treatment urarthritis preparation is prepared |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2937094T3 (en) | Pharmaceutical composition for use in the treatment of headaches and their preparation | |
| CN101513519B (en) | Chinese medicinal composition for invigorating Qi and nourishing blood, preparation method and quality control method thereof | |
| CN105079308A (en) | Common rockvine herb extract as well as preparation method and pharmaceutical application of extract | |
| CN105031070A (en) | Viola tricolor extract for treating gouty arthritis and preparation method thereof | |
| CN1977889B (en) | Medicinal composition of astragalus, salvia miltrorrhiza and oxymatrine, and its preparing method | |
| CN105232627A (en) | Solidago extract and preparation method and medical application thereof | |
| CN105232619A (en) | Lysimachia trientaloides hemsl. extract as well as preparation method and medical application thereof | |
| CN105147907A (en) | Dasheen flower extract, as well as preparation method and medicinal application thereof | |
| CN101011566A (en) | Medicine composition for treating chronic pelvic inflammatory disease, preparing method and quality controlling method thereof | |
| CN105168305A (en) | Hungaian morningglory root extract for treating gouty arthritis | |
| CN102397522A (en) | Preparation method of novel biochemical particles | |
| CN101642492B (en) | Drug for treating chronic pelvic inflammatory disease and preparation method thereof | |
| CN103908631A (en) | Traditional Chinese medicinal compound extract with anti-breast hyperplasia effect and preparation method thereof | |
| CN105535039A (en) | Japanese nanocnide herb extract and medical application thereof in treatment of gouty arthritis | |
| CN103816223B (en) | Sugarless type Chuan Xiong Tea particle | |
| CN102631386B (en) | Bupleurum antipyretic and analgesic preparation and technology for preparing same | |
| CN105412186A (en) | Extracting preparation method for traditional Chinese medicinal material containing volatile oil and composition of traditional Chinese medicinal material | |
| CN104189833A (en) | Process for preparing xiaoyao pills | |
| CN100998788B (en) | Traditional Chinese medicine composition dripping for treating gastrointestinal disease and its preparing method | |
| CN107397817A (en) | Willow leaf extract and its production and use | |
| CN105106274A (en) | Sabia schumanniana extract, preparing method thereof and medical application thereof | |
| CN105106558A (en) | Brain aging resistance hosta ventricosa extract and preparation method | |
| CN105079144A (en) | Cimicifugae foetidae extract having effects of diminishing inflammation and relieving pain and preparation method of cimicifugae foetidae extract | |
| CN104740570A (en) | Medicament with effects of dispelling wind, eliminating dampness and relieving swelling and pain as well as preparation method and application thereof | |
| CN105125622A (en) | Rubus obcordatus extract with immunological enhancement effect and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 311802, Shaoxing City, Zhejiang province Zhuji Ruan Town soup Village Applicant after: Zhuang Li Address before: 325016 Zhejiang Province, Wenzhou city Ouhai District streets Quxi Road No. 26 reform Applicant before: Zhuang Li |
|
| COR | Change of bibliographic data | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160113 |
|
| WW01 | Invention patent application withdrawn after publication |